Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

SK Biopharmaceuticals Enters MENA through Strategic Partnership with Hikma

Saturday, August 19, 2023

SK Biopharmaceuticals has entered into strategic and licencing agreements with Hikma to expand its presence into the Middle East and North Africa (MENA) region.

The agreement between SK Biopharmaceuticals and Hikma provides Hikma with exclusive rights to commercialise cenobamate, a drug developed by SK Biopharmaceuticals, in the Middle East and North Africa (MENA) region.

This exclusive commercialisation right extends to some of the most significant countries in the region, including Saudi Arabia, Egypt, and Algeria. This collaboration follows SK Biopharmaceuticals' efforts to expand its reach globally, as they have already ventured into North America, Northeast Asia, and Latin America to enhance patient access to cenobamate on a worldwide scale.

The partnership with Hikma is another step towards achieving these goals, and it signifies SK Biopharmaceuticals' dedication to expanding their market presence and making their innovative medications available to patients in regions where there is a significant medical need.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024